Earnings ·
PMV Pharmaceuticals reported second quarter 2026 financial results on August 14, 2026
PMVPPMV Pharmaceuticals, Inc.
PMV Pharmaceuticals reported second quarter 2026 financial results on August 14, 2026. The company ended the quarter with $79.4 million in cash and marketable securities, down from $112.9 million at year-end 2025. Net loss for the quarter was $18.1 million, compared to $21.2 million in the prior-year period, driven by lower contract research organization costs. Research and development expenses decreased to $14.7 million from $18.4 million. Clinically, enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE trial has been completed. The company plans to submit a New Drug Application (NDA) for accelerated approval of rezatapopt for this indication in the first quarter of 2027, with an expected cash runway through the second quarter of 2027. PMV Pharmaceuticals is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53.